Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
RMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$179.42 - $263.05
Previous CloseN/A
Volume178.41K
Average Volume (3M)1.16M
Market Cap
$34.68B
Enterprise Value$32.86B
Total Cash (Recent Filing)$520.94M
Total Debt (Recent Filing)$143.70M
Price to Earnings (P/E)26.5
Beta1.08
Next Earnings
Jul 31, 2025EPS Estimate
2.47Next Dividend Ex-Date
May 08, 2025Dividend Yield0.96%
Share Statistics
EPS (TTM)8.91
Shares Outstanding146,866,910
10 Day Avg. Volume1,468,419
30 Day Avg. Volume1,155,425
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)N/A
Price to Sales (P/S)6.55
Price to Cash Flow (P/CF)26.10
P/FCF Ratio26.10
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.38
Enterprise Value/Ebitda19.84
Forecast
1Y Price Target
$264.44Price Target Upside12.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company experienced a 140 basis points gross margin expansion, reaching a level not seen since 2Q21, indicating strong financial performance.
Share Buyback ProgramStrong cash generation has allowed Resmed to extend its buyback program, increasing it to $100 million per quarter, which is a positive signal to investors.
Tariff ExemptionResmed confirms CPAP products are exempt from tariffs under the Nairobi Protocol, which is a favorable development for the company.
Bears Say
GLP-1 Drug RiskGiven the risk posed by the FDA approval of the first GLP-1 drug for obstructive sleep apnea (OSA) and Medicare's coverage of the drug for OSA, we maintain our Hold rating.
GLP-1 Medications ChallengeThe increasing prominence of GLP-1 medications is expected to pose several challenges for the CPAP market.
Tariff ImpactA 10% baseline tariff applied to AUS and SNG products could negatively impact Resmed Inc's financial performance.
---
Ownership Overview
0.52% Insiders
17.00% Mutual Funds
0.66% Other Institutional Investors
57.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $179.42 and its highest was $263.05 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $34.68B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Jul 31, 2025 which is in 96 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Apr 23, 2025. The company reported $2.37 earnings per share for the quarter, missing the consensus estimate of $2.378 by -$0.008.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $2.066 which represents an annual dividend yield of 0.96%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.47.
How many shares outstanding does Resmed have?
Resmed has 146,866,910 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.37 in its last earnings report, missing expectations of $2.378. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
---
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$264.44 (12.00% Upside)
$264.44 (12.00% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $499.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.63%
12-Months-Change
Fundamentals
Return on Equity
25.81%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. (RMD) is a global leader in the development, manufacturing, and distribution of innovative solutions for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory disorders. The company operates primarily in the healthcare sector, providing cloud-connected devices and healthcare informatics solutions designed to improve patient outcomes and reduce healthcare costs. ResMed's core products include continuous positive airway pressure (CPAP) devices, ventilators, and a range of accessories, along with software solutions that facilitate remote monitoring and management of patients.
---
RMD Company Deck
---
RMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, gross margin expansion, successful product launches, and increased share buybacks. Despite challenges such as sleep lab backlogs and foreign currency impacts, ResMed demonstrated resilience with strategic expansions and maintaining tariff exemptions.Read More>---
RMD Revenue Breakdown
87.53% Sleep and Respiratory Care
12.47% Software as a Service
---
RMD Stock 12 Month Forecast
Average Price Target
$264.44
▲(12.00% Upside)
Technical Analysis
Best Analysts Covering RMD
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+7.95%
reiterated a buy rating 2 days ago
Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +7.95% per trade.
---